지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2012.1
- 수록면
- 414 - 422 (9page)
이용수
초록· 키워드
오류제보하기
Purpose: The purpose of this study was to determine the pharmacogenetic effects of complement factor H (CFH) Y402H, LOC387715 and high-temperature requirement factor A1 (HTRA1) genotypes on the treatment of exudative age-related macular degeneration (AMD) by intravitreal bevacizumab injection in a Korean population.
Methods: Seventy-five patients diagnosed with exudative AMD were treated with intravitreal bevacizumab (2.5 mg) monotherapy. All patients received three initial intravitreal bevacizumab injections every four weeks and were then treated “as needed” based on clinical findings, optical coherence tomography and fluorescein angiography during the 12 month follow-up period after the third injection.
Results: The difference in visual acuity improvement among the three genotypes of LOC387715 were statistically significant at six months post-treatment (logarithm of the minimum angle of resolution; TT, 0.346; GT, 0.264; GG, 0.188; p = 0.037). Among the LOC387715 genotypes, the number of additional injections was lower in patients who had the risk T allele (GG, 2.143; GT, 2.000; TT, 1.575; p = 0.064). There was no significant difference between visual acuity and central macular thickness change in the CFH Y402H polymorphism group during the 12 month follow-up period. However, the TC group of CFH Y402H required more additional bevacizumab injections than the TT group (TT, 1.517; TC, 3.363; p = 0.020).
Conclusions: This study demonstrated that different LOC387715/HTRA1 genotypes resulted in different bevacizumab treatment responses on exudative AMD. Patients with the risk allele had an improved treatment response and less need for additional injections. However, patients with the CFH Y402H risk allele needed more additional injections of bevacizumab in order to improve visual acuity. This study illustrates how pharmacogenetic factors may help determine treatment modality and dosing. This could ultimately provide basic data for ‘personalized medicine’ in AMD.
목차
등록된 정보가 없습니다.
참고문헌 (24)
참고문헌 신청
Age-Related Eye Disease Study Research Group / 2000 / Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study
Ambati J / 2003 / Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies / Surv Ophthalmol 48 : 257 ~ 293
Cackett P / 2008 / Smoking, cardiovascular risk factors, and age-related macular degeneration in Asians: the Singapore Malay Eye Study / Am J Ophthalmol 146 : 960 ~ 967
Conley YP / 2006 / CFH, ELOVL4, PLEKHA1 and LOC387715 genes and susceptibility to age-related maculopathy: AREDS and CHS cohorts and meta-analyses / Hum Mol Genet 15 : 3206
Dandekar SS / 2006 / Does smoking influence the type of age related macular degeneration causing visual impairment? / Br J Ophthalmol 90 : 724 ~ 727
Ambati J / 2003 / Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies / Surv Ophthalmol 48 : 257 ~ 293
Cackett P / 2008 / Smoking, cardiovascular risk factors, and age-related macular degeneration in Asians: the Singapore Malay Eye Study / Am J Ophthalmol 146 : 960 ~ 967
Conley YP / 2006 / CFH, ELOVL4, PLEKHA1 and LOC387715 genes and susceptibility to age-related maculopathy: AREDS and CHS cohorts and meta-analyses / Hum Mol Genet 15 : 3206
Dandekar SS / 2006 / Does smoking influence the type of age related macular degeneration causing visual impairment? / Br J Ophthalmol 90 : 724 ~ 727
이 논문의 저자 정보
최근 본 자료
댓글(0)
0